NCT00655512

Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream, Hydrocortisonacetat 1% Cream, Betamethasonvalerat 0,1% Cream and Clobetasol-17-propionat 0,05% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound

Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream (Elidel® 1% Cream), Hydrocortisonacetat 1% Cream (Hydrogalen® Cream), Betamethasonvalerat 0,1% Cream (Betagalen® Cream) and Clobetasol-17-propionat 0,05% Cream (Clobegalen® Cream) Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound - a Single Blind, Placebo-controlled, Randomized, Monocenter Clinical Trial

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Technische Universität Dresden · Academic / Other
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

to compare the atrophogenic potentials of pimecrolimus 1% cream, hydrocortisonacetat 1% cream, betamethasonvalerat 0,1% cream and clobetasol-17-Propionat 0,05% cream

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	pimecrolimus 1% cream	twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
DRUG	hydrocortisonacetat 1% cream	twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
DRUG	betamethasonvalerat 0,1% cream	twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
DRUG	clobetasol-17-propionat 0,05% cream	twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
DRUG	Placebo	twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks

Timeline

• Start date: 2008-01-01
• Primary completion: 2008-06-01
• Completion: 2008-10-01
• First posted: 2008-04-10
• Last updated: 2014-06-11

Locations

1 site across 1 country: Germany